Logo image of BNGO

BIONANO GENOMICS INC (BNGO) Stock Fundamental Analysis

NASDAQ:BNGO - Nasdaq - US09075F4046 - Common Stock - Currency: USD

3.43  +0.03 (+0.88%)

After market: 3.4882 +0.06 (+1.7%)

Fundamental Rating

2

BNGO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. BNGO has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, BNGO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BNGO had negative earnings in the past year.
BNGO had a negative operating cash flow in the past year.
BNGO had negative earnings in each of the past 5 years.
In the past 5 years BNGO always reported negative operating cash flow.
BNGO Yearly Net Income VS EBIT VS OCF VS FCFBNGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of BNGO (-106.74%) is worse than 92.86% of its industry peers.
With a Return On Equity value of -173.69%, BNGO is not doing good in the industry: 82.14% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -106.74%
ROE -173.69%
ROIC N/A
ROA(3y)-99.22%
ROA(5y)-76.96%
ROE(3y)-203.87%
ROE(5y)-150.04%
ROIC(3y)N/A
ROIC(5y)N/A
BNGO Yearly ROA, ROE, ROICBNGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

With a Gross Margin value of 1.74%, BNGO is not doing good in the industry: 91.07% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of BNGO has declined.
The Profit Margin and Operating Margin are not available for BNGO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-61.43%
GM growth 5Y-48.22%
BNGO Yearly Profit, Operating, Gross MarginsBNGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

3

2. Health

2.1 Basic Checks

BNGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
BNGO has less shares outstanding than it did 1 year ago.
The number of shares outstanding for BNGO has been reduced compared to 5 years ago.
BNGO has a worse debt/assets ratio than last year.
BNGO Yearly Shares OutstandingBNGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
BNGO Yearly Total Debt VS Total AssetsBNGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

BNGO has an Altman-Z score of -14.03. This is a bad value and indicates that BNGO is not financially healthy and even has some risk of bankruptcy.
BNGO's Altman-Z score of -14.03 is on the low side compared to the rest of the industry. BNGO is outperformed by 96.43% of its industry peers.
BNGO has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BNGO (0.07) is better than 66.07% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -14.03
ROIC/WACCN/A
WACC63.92%
BNGO Yearly LT Debt VS Equity VS FCFBNGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

BNGO has a Current Ratio of 1.70. This is a normal value and indicates that BNGO is financially healthy and should not expect problems in meeting its short term obligations.
BNGO has a Current ratio of 1.70. This is in the lower half of the industry: BNGO underperforms 69.64% of its industry peers.
A Quick Ratio of 1.34 indicates that BNGO should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.34, BNGO is doing worse than 66.07% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.34
BNGO Yearly Current Assets VS Current LiabilitesBNGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

BNGO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.42%, which is quite impressive.
Looking at the last year, BNGO shows a very negative growth in Revenue. The Revenue has decreased by -24.04% in the last year.
BNGO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.89% yearly.
EPS 1Y (TTM)71.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.24%
Revenue 1Y (TTM)-24.04%
Revenue growth 3Y19.62%
Revenue growth 5Y24.89%
Sales Q2Q%-26.37%

3.2 Future

BNGO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.92% yearly.
The Revenue is expected to grow by 22.92% on average over the next years. This is a very strong growth
EPS Next Y91.17%
EPS Next 2Y39.66%
EPS Next 3Y25.64%
EPS Next 5Y14.92%
Revenue Next Year4.45%
Revenue Next 2Y9.86%
Revenue Next 3Y22.13%
Revenue Next 5Y22.92%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BNGO Yearly Revenue VS EstimatesBNGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
BNGO Yearly EPS VS EstimatesBNGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNGO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNGO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNGO Price Earnings VS Forward Price EarningsBNGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNGO Per share dataBNGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40

4.3 Compensation for Growth

A more expensive valuation may be justified as BNGO's earnings are expected to grow with 25.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.66%
EPS Next 3Y25.64%

More info and screens

0

5. Dividend

5.1 Amount

BNGO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONANO GENOMICS INC

NASDAQ:BNGO (7/18/2025, 8:00:01 PM)

After market: 3.4882 +0.06 (+1.7%)

3.43

+0.03 (+0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners9.13%
Inst Owner Change0%
Ins Owners0.05%
Ins Owner Change-0.01%
Market Cap11.52M
Analysts78
Price Target7.48 (118.08%)
Short Float %14.82%
Short Ratio5.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-47.99%
Min EPS beat(2)-158.66%
Max EPS beat(2)62.68%
EPS beat(4)2
Avg EPS beat(4)-33.62%
Min EPS beat(4)-158.66%
Max EPS beat(4)62.68%
EPS beat(8)4
Avg EPS beat(8)-9.6%
EPS beat(12)5
Avg EPS beat(12)-9.29%
EPS beat(16)5
Avg EPS beat(16)-14.65%
Revenue beat(2)2
Avg Revenue beat(2)15.32%
Min Revenue beat(2)1.56%
Max Revenue beat(2)29.08%
Revenue beat(4)3
Avg Revenue beat(4)6.93%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)29.08%
Revenue beat(8)6
Avg Revenue beat(8)3.9%
Revenue beat(12)9
Avg Revenue beat(12)3.25%
Revenue beat(16)12
Avg Revenue beat(16)3.99%
PT rev (1m)0%
PT rev (3m)-87.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.18%
EPS NY rev (1m)0%
EPS NY rev (3m)12.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.4
P/FCF N/A
P/OCF N/A
P/B 0.24
P/tB 0.29
EV/EBITDA N/A
EPS(TTM)-54.18
EYN/A
EPS(NY)-4.15
Fwd EYN/A
FCF(TTM)-12.99
FCFYN/A
OCF(TTM)-12.96
OCFYN/A
SpS8.47
BVpS14.34
TBVpS11.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -106.74%
ROE -173.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1.74%
FCFM N/A
ROA(3y)-99.22%
ROA(5y)-76.96%
ROE(3y)-203.87%
ROE(5y)-150.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-61.43%
GM growth 5Y-48.22%
F-Score4
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.56%
Cap/Sales 0.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.7
Quick Ratio 1.34
Altman-Z -14.03
F-Score4
WACC63.92%
ROIC/WACCN/A
Cap/Depr(3y)12.46%
Cap/Depr(5y)12.34%
Cap/Sales(3y)4.56%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.24%
EPS Next Y91.17%
EPS Next 2Y39.66%
EPS Next 3Y25.64%
EPS Next 5Y14.92%
Revenue 1Y (TTM)-24.04%
Revenue growth 3Y19.62%
Revenue growth 5Y24.89%
Sales Q2Q%-26.37%
Revenue Next Year4.45%
Revenue Next 2Y9.86%
Revenue Next 3Y22.13%
Revenue Next 5Y22.92%
EBIT growth 1Y53.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year88.4%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.08%
OCF growth 3YN/A
OCF growth 5YN/A